EGFR and non-small cell lung carcinoma: Notably, our results that H1975 cells harboring L858R/T790M double epidermal growth factor receptor (EGFR)-tyrosine kinase mutations making them resistant to both first- and second-generation EGFR-tyrosine kinase inhibitors were susceptible to CVA11 infection leading to their cytolytic destruction (Fig. 1A) suggested its potential antitumor activity against refractory NSCLC patients with driver genetic abnormalities.